Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 39 of 95, showing 5 Applications out of 471 total, starting on record 191, ending on 195

# Protocol No Study Title Investigator(s) & Site(s)

191.

ECCT/18/12/01   study to determine if a new malaria vaccine is safe and induces immunity among Kenyan adults, young children and infants.
    A Phase 1b, open-label, age de-escalation, dose-escalation study to evaluate the safety and immunogenicity of different doses of a candidate malaria vaccine; adjuvanted R21(R21/MM) in adults, young children and infants in Kilifi, Kenya.   
Principal Investigator(s)
1. Mainga Hamaluba
Site(s) in Kenya
KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya.
 
View

192.

ECCT/18/12/02   Randomized Controlled Trial to Compare the Effect of Corn-Soy Blend + Vegetable Oil 8 and Fish Oil (CSB-VO-FO) With Corn-Soy Blend + Vegetable Oil Alone (CSB-VO) on 9 the Immunological and Microbiota Patterns among Children Aged 6 to 24 months with 10 Mod
    Randomized Controlled Trial to Compare the Effect of Corn-Soy Blend + Vegetable Oil 8 and Fish Oil (CSB-VO-FO) With Corn-Soy Blend + Vegetable Oil Alone (CSB-VO) on 9 the Immunological and Microbiota Patterns among Children Aged 6 to 24 months with 10 Mod   
Principal Investigator(s)
1. CHRISTOPHER L. MELBY MELBY
Site(s) in Kenya
KENYA MEDICAL RESEARCH INSTITUTE
 
View

193.

ECCT/19/01/01   A Randomized, Open, Parallel-group, Single Dose, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel in combination with Ferroquine (FQ) and FQ alone, in African Patients with Unc
    A Randomized, Open label, Parallel-group, Single Dose Regimen, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel (OZ439) given in combination with Ferroquine (FQ) and FQ alone, in African Patients with Uncomplicated Plasmodium falciparum Malaria   
Principal Investigator(s)
1. Bernhards Ogutu Ragama
Site(s) in Kenya
1. Ahero County hospital (Kisumu county)
2. Siaya County Hospital (Siaya county)
 
View

194.

ECCT/19/01/02   Opt4Kids
    Optimizing viral load suppression in Kenyan children on antiretroviral therapy (Opt4Kids)   
Principal Investigator(s)
1. Lisa Dillabaugh Abuogi
2. Patrick Oyaro Owiti
Site(s) in Kenya
1. Kisumu County Hospital (Kisumu county)
2. Ahero County Hospital (Kisumu county)
3. Nyakach County Hospital (Kisumu county)
4. Lumumba sub-County Hospital (Kisumu county)
5. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
 
View

195.

ECCT/19/02/01   DANCE Study
    An Open-Label, Single Arm Study to Evaluate the Week 48 Efficacy and Safety of a Two-Drug Regimen of Dolutegravir/Lamivudine (DTG/3TC) as a Fixed Dose Combination (FDC), in Antiretroviral Therapy (ART)-Naive HIV-1-Infected Adolescents, ≥12 To <18 Years of Age who Weigh at Least 40 Kg.   
Principal Investigator(s)
1. Fredrick Odhiambo Otieno
2. Isaac Tsikhutsu
Site(s) in Kenya
1. Nyanza Reproductive Health Society (Kisumu county)
2. Kenya Medical Research Institute (Kisumu county)
3. Kenya Medical Research Institute, Walter Reed Project (Kericho county)
 
View